Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
Prasad A, Arora A, Arora A, Vaid J, Khan A
Summary
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subjects compared GLP-1 RAs, GLP-1/GIP dual agonists (tirzepatide), and older non-GLP weight loss agents using patient-exposure year normalization. GLP-1/GIP dual agonists demonstrated the greatest weight loss, with tirzepatide and liraglutide leading efficacy outcomes. Mortality rate ratios were favorable across most GLP-1 trials (RR 0.1-0.7) compared to non-GLP agents (RR 0.8).
Clinical Significance
This large-scale FDA-level analysis provides clinicians with exposure-adjusted safety comparisons that go beyond individual trial data. The finding that GLP-1/GIP dual agonists achieve superior weight loss with favorable mortality signals supports tirzepatide's positioning as the most effective incretin-based weight management option, while postmarketing neoplasm rates (0.7% for dual agonists vs 5.4% for weight management GLP-1 RAs) warrant continued pharmacovigilance.
Related Research
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
GLP-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control
This review synthesizes preclinical and clinical evidence showing that GLP-1 RAs may reduce platelet…
GLP-1 Drugs, Gastrointestinal Function and Critical Illness
This review addresses the peri-operative and ICU management of patients on long-acting GLP-1 therapy…